Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.47 USD | -2.61% | +0.27% | -14.63% |
04:29pm | Morgan Stanley Adjusts COMPASS Pathways Price Target to $23 From $30, Maintains Overweight Rating | MT |
06-04 | FDA panel to review psychedelic drug MDMA for first time | RE |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.63% | 524M | |
+55.70% | 55.7B | |
+41.08% | 39.91B | |
-5.39% | 39.57B | |
-5.56% | 28.16B | |
+16.46% | 26.3B | |
-20.56% | 18.94B | |
+33.03% | 12.17B | |
+25.85% | 12.12B | |
+2.72% | 12.12B |
- Stock Market
- Equities
- CMPS Stock
- News COMPASS Pathways plc
- Transcript : COMPASS Pathways plc, Q2 2021 Earnings Call, Aug 11, 2021